

FATEMEH KHOSRAVI SHADMANI

E-mail: khosravishadman@gmail.com

Mobile: 09183857297

EDUCATION

2014-2019 *Ph.D. in Epidemiology*
Kerman University of Medical Sciences, Kerman, Iran
Thesis title: “National and subnational levels achievement to Sustainable Development Goals (SDGs) for non- communicable diseases in Iran: modelling study with scenario-based projection”

Supervisors: *Ali Akbar Haghdooost, Farshad Farzadfar, Bagher Larijani*

2010-2013 *Master in Epidemiology*
Shahid Beheshti University of Medical Sciences, Tehran, Iran
Thesis title: “Estimating the potential impact fraction of the preventive interventions for road traffic injuries in Iran”

Supervisors: *Hamid Soori, Manoochehr Karami, Farid Zayeri*

2007-2010 *Bachelor in Public Health*
Iran University of Medical Sciences, Tehran, Iran

WORK EXPERIENCE

- *Assistant Professor in Epidemiology, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, June 2025*
- *Director of Registration systems for diseases and other health outcomes, Kermanshah, Iran, June 2025*
- *Director of Health Observatory at Kermanshah University of Medical Sciences, Kermanshah, Iran, October 2024*

- *Assistant Professor in Epidemiology, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran, June 2025*
- *Working in Health Observatory in MOHME since August 2018*
- *Collaboration with Safety Promotion and Injury Prevention Research Centre (SPIPRC) – Shahid Beheshti University of Medical Sciences*
- *Collaboration with Research Centre for Environmental Determinants of Health (RCEDH), Kermanshah University of Medical Sciences*
- *Collaboration with liver diseases research centre , Kermanshah University of Medical Sciences*
- *Consultant in Clinical Research Development Unit ,Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah*
- *Consultant in Clinical Research Development Unit ,Imam khomeini Hospital, Kermanshah University of Medical Sciences, Kermanshah*
- *Consultant in social Development & Health Promotion Research Centre, Kermanshah University of Medical Sciences, Kermanshah*
- *Collaboration with Non Communicable Diseases Reasearch Centre (NCDRC), Tehran University of Medical Sciences, ongoing*

AWARDS & HONOURS

2015 *Awarded with the best article prize from Iranian epidemiology association*

2017 *The top student at Kerman University of Medical Sciences*

2019 *The top Ph.D thesis in epidemiology in Iran*

PUBLICATIONS & PRESENTATIONS

➤ Selected Published Articles

1. Darabi F, Najafi Z, Arvan K, Mohammadi N, **Shadmani FK**, Soltani S. Quality of life among people with disabilities and its related factors in Iran: a cross-sectional study. *BMC Public Health*. 2025 Dec;25(1):1-9.
2. Mirzaei SK, Hatami F, Safi S, Khorrami Z, **Shadmani FK**, Moshtaghion SM, Ahmadi H. Pharmacological agents for treatment of proliferative vitreoretinopathy: A systematic review and network meta-analysis. *Survey of Ophthalmology*. 2025 Mar 1.
3. Darbandi M, Khorrami Z, Karamoozian A, Aboubakri O, Miryan M, Rezakhani L, **Shadmani FK**. A comparison of the burden of cancers between 1990 and 2019 in Iran: A national and subnational study. *PloS one*. 2025 Feb 25;20(2):e0309699.
4. Soltani S, Moradinazar M, Karamimatin B, Gouya MM, Zahraei SM, Moradi G, Chehri O, Soofi M, **Shadmani FK**, Kalantari M, Najafi F. Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study. *BMC Public Health*. 2025 Feb 17;25(1):650.
5. **Shadmani FK**, Gheshlaghi LA, Jafari-Khounigh A, Rezakhani L, Khazaei M. Burden and mortality of breast cancer attributed to diabetes and smoking in women: a secondary analysis based on Global Burden of Disease 2019 in North Africa and the Middle East. *BMJ open*. 2025 Jan 1;15(1):e087178.
6. Sedaghat M, Karami B, Najafi F, **Shadmani FK**, Rezaeian S. Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers. *Vaccine*. 2024 Dec 2;42(26):126424.
7. Zangeneh A, Hamidipour N, Khazir Z, Ziapour A, Molavi H, Kiaee ZG, Teimouri R, Shakiba E, Soofi M, **Khosravi Shadmani F**. Spatiotemporal modeling of COVID-19 spread: unveiling socioeconomic disparities and patterns, across social classes in the urban population of Kermanshah, Iran. *Frontiers in Public Health*. 2024 Oct 4;12:1400629.
8. Karimi R, Farrokhi M, Izadi N, Ghajari H, **Shadmani FK**, Najafi F, Shakiba E, Karami M, Shojaeian M, Moradi G, Ghaderi E. Basic Reproduction Number (R0), Doubling Time, and Daily Growth Rate of the COVID-19 Epidemic: An Echological Study. *Archives of Academic Emergency Medicine*. 2024 Sep 5;12(1):e66.

9. **Khosravi Shadmani F**, Moradi G, Naghipour M, Torkaman Asadi F, Ahmadi A, Mirahmadizadeh A, Haghdooost A, Mesgarpour B, Zahraei SM, Gouya MM, Mokhtari M. Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study. *Frontiers in Immunology*.;15:1420651.
10. Runge M, Karimian Z, Kheirandish M, Borghi G, Wodniak N, Fahmy K, Mantel C, Cherian T, Nabil Ahmed Said Z, Najafi F, Thneibat F, ..., **Khosravi Shadmani F**, COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region. *Vaccines*. 2024 Aug 10;12(8):906.
11. Najafi F, Moradinazar M, **Khosravi Shadmani F**, Pasdar Y, Darbandi M, Salimi Y, Ghasemi SR. The incidence of diabetes mellitus and its determining factors in a Kurdish population: insights from a cohort study in western Iran. *Scientific Reports*. 2024 Jul 9;14(1):15761.
12. Zangeneh A, Najafi F, Khosravi A, Ziapour A, Molavi H, Moradi Z, Bakhshi S, **Shadmani FK**, Karamimatin B, Soofi M. Epidemiological patterns and spatiotemporal analysis of cardiovascular disease mortality in Iran: Development of public health strategies and policies. *Current Problems in Cardiology*. 2024 Aug 1;49(8):102675.
13. Zomorodi Zare F, **Khosravi Shadmani F**, Safari Faramani R, Torkamanasadi F, Rezaei Y, Najafi F. Evaluating the Effectiveness of the COVID-19 Vaccines on Infection Indicators and Severe Outcomes in Hamadan Province (2021-2022). *Iranian Journal of Epidemiology*. 2024 Jun 10;20(1):35-44.
14. Morovati S, Bozorgomid A, Mohammadi A, Ahmadi F, Arghand L, **Khosravi Shadmani F**, Sayad B. Brucellar arthritis and sacroiliitis: an 8-year retrospective comparative analysis of demographic, clinical, and paraclinical features. *Therapeutic Advances in Infectious Disease*. 2024 May;11:20499361241246937.
15. Farzadfar F, Yousefi M, Jafari-Khounigh A, Khorrami Z, Haghdooost A, **Shadmani FK**. Trend and projection of non-communicable diseases risk factors in Iran from 2001 to 2030. *Scientific Reports*. 2024 Apr 6;14(1):8092.
16. Farnia V, Ahmadi Jouybari T, Salemi S, Moradinazar M, **Khosravi Shadmani F**, Rahami B, Alikhi M, Bahadorinia S, Mohammadi Majd T. The prevalence of alcohol consumption and its related factors in adolescents: Findings from Global School-based Student Health Survey. *PLoS one*. 2024 Apr 1;19(4):e0297225.

17. Pasdar Y, Rezaeian S, Mohammadi E, **Khosravi shadmani F**, Shahnazi N, Najafi F, Nazar MM, Darbandi M. The interaction between general or abdominal obesity and hypertension on the risk of type 2 diabetes mellitus: a cross-sectional analysis in Iranian adults from the RaNCD cohort study. *BMC Public Health*. 2024 Mar 11;24(1):752.
18. Pasdar Y, **Shadmani FK**, Fateh HL, Soleimani D, Hamzeh B, Ghalandari M, Moloudpour B, Darbandi M. The burden of colorectal cancer attributable to dietary risk in Middle East and North African from 1990 to 2019. *Scientific Reports*. 2023 Nov 20;13(1):20244.
19. Darbandi, M., Rezaeian, S., Najafi, F., **Shadmani, F.K.**, Ghavi, S., Miryan, M., Pasdar, Y. and Barzegar, A., 2023. A Comprehensive Evaluation of Occupational Epidemiology in Western Iran: A Cohort Study in Ravansar Noncommunicable Diseases. *Journal of Occupational and Environmental Medicine*, 65(9), pp.e610-e618.
20. Soltani S, Matin BK, Gouya MM, Zahraei SM, Moradi G, Chehri O, Soofi M, Moradinazar M, **Shadmani FK**, Kalantari M, Khajeha H. A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran. *BMC Public Health*. 2023 Jul 24;23(1):1415.
21. Darbandi M, **Shadmani FK**, Miryan M, Ghalandari M, Mohebi M, Jam SA, Pasdar Y. The burden of osteoarthritis due to high Body Mass Index in Iran from 1990 to 2019. *Scientific Reports*. 2023 Jul 20;13(1):11710.
22. Jesmani Y, Bozorgomid A, **Shadmani FK**, Dehbani A, Sayad B. Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave. *Vacunas (English Edition)*. 2023 Jul 1;24(3):182-9.
23. **Shadmani FK**, Najafi F, Mansori K, Moradi MR, Rezaei M, Rezvani N, Darbandi M, Yoosefi M, Laghei Z, Bozorgomid A, Salahshoor P. Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study. *The Open Public Health Journal*. 2023 Mar 29;16(1).
24. Rezakhani L, Khazaei M, Vaziri S, **Khosravi Shadmani F**. Mortality among COVID-19 Patients with Different Comorbidities in Kermanshah, West of Iran (2020). *Journal of Occupational Health and Epidemiology*. 2023 Mar 10;12(1):4-11.
25. Rezakhani L, Darbandi M, Khorrami Z, Rahmati S, **Shadmani FK***. Mortality and disability-adjusted life years for smoking-attributed cancers from 1990 to 2019 in the north Africa and middle east countries: a systematic analysis for the global burden of disease study 2019. *BMC cancer*. 2023 Jan 24;23(1):80.
26. Haghdooost AA, Farzadfar F, Yoosefi M, Mansori K, Larijani B, Baneshi MR, **Shadmani FK**. Iran to achieve the SDG 3.4 at national and sub-national levels. *Scientific reports*. 2022 Mar 8;12(1):1-3.

27. **Khosravi Shadmani F**, Farzadfar F, Yoosefi M, Mansori K, Shadman RK, Haghdooost AA. *Premature Mortality of Gastrointestinal Cancer in Iran: Trends and Projections for 2001–2030. BMC cancer. 2020Dec;20(1):1-0.*
28. **Khosravi Shadmani F**, Kamalian A, Yoosefi M, Mohajer B, Mohebi F, Naderimagham S, Rezaei N, Ghasemi E, Rouhifard Khalilabad M, Hassanmirzaei B, Selk Ghaffari M. *A national and sub-national metaregression of the trend of insufficient physical activity among Iranian adults between 2001 and 2016. Scientific Reports. 2021 Nov 2;11(1):1-9.*
29. **Khosravi Shadmani F**, Farzadfar F, Larijani B, Mirzaei M, Haghdooost AA. *Trend and projection of mortality rate due to non-communicable diseases in Iran: A modeling study. PLoS ONE. 2019 Feb 14;14(2).*
30. **Shadmani FK**, Amanollahi A, Zali A, Najafi F, Karami M, Moradi G, Mohammadian-Hafshejani A, Ahmadi A, Sartipi M, Shojaeian M, Noori E. *Description of epidemiological features, symptoms and mortality of the patients with COVID-19 in some provinces of Iran. Archives of Iranian medicine. 2021;24(10):733-40.*
31. Hesni E, Sayad B, **Khosravi Shadmani F**, Najafi F, Khodarahmi R, Rahimi Z, Bozorgomid A, Sayad N. *Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study. BMC infectious diseases. 2022 Dec;22(1):1-2.*
32. Nakhaee S, **Shadmani FK**, Sharafi K, Kiani A, Azadi NA, Mansouri B, Karamimatin B, Farnia V. *Evaluation of some toxic metals in breast milk samples with dietary and sociodemographic characteristics: a case study of Kermanshah, Western Iran. Environmental Science and Pollution Research. 2022 Aug 15:1-8.*
33. Zanganeh A, Yenneti K, Teimouri R, Saeidi S, Najafi F, Shakiba E, Moghadam S, **Shadmani FK**. *The Spatiality of COVID-19 in Kermanshah Metropolis, Iran. Urban Science. 2022 Apr 22;6(2):30.*
34. Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A, **Shadmani FK**. *Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021 Aug;76(8):2158-67.*
35. Sayad B, Mehrabi M, Khodarahmi R, Najafi F, Miladi R, Afshar ZM, Mansouri F, Shirvani M, Salimi M, **Shadmani FK**. *Clinical effectiveness and safety of sofosbuvir–*

velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial. Journal of Reports in Pharmaceutical Sciences. 2021 Jul 1;10(2):294.

36. **Shadmani FK**, Amanollahi A, Zali A, Najafi F, Karami M, Moradi G, Mohammadian-Hafshejani A, Ahmadi A, Sartipi M, Shojaeian M, Noori E. Description of epidemiological features, symptoms and mortality of the patients with COVID-19 in some provinces of Iran. *Archives of Iranian Medicine. 2021;24(10):733-40.*

37. Reshadat S, Zangeneh A, Ziapour A, Farahmandmoghadam N, **Khosravi Shadmani F**, Teimouri R, Golanbari SZ, Rostami S. A survey of statistical methods for inequalities in access to healthcare Kermanshah in West Iran. *Frontiers in Applied Mathematics and Statistics. 2022;8.*

38. Kamalian A, **Khosravi Shadmani F**, Yoosefi M, Mohajer B, Mohebi F, Naderimagham S, Rezaei N, Ghasemi E, Rouhifard Khalilabad M, Hassanmirzaei B, Selk Ghaffari M. A national and sub-national metaregression of the trend of insufficient physical activity among Iranian adults between 2001 and 2016. *Scientific Reports. 2021 Nov 2;11(1):1-9.*

39. Sayad, B., Mehrabi, M., Khodarahmi, R., Najafi, F., Miladi, R., Afshar, Z.M., Mansouri, F., Shirvani, M., Salimi, M. and **Shadmani, F.K.**, 2021. Clinical effectiveness and safety of sofosbuvir–velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial. *Journal of Reports in Pharmaceutical Sciences, 10(2), p.294.*

40. Sayad B, Khodarahmi R, Najafi F, Miladi R, Afshar ZM, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. *Journal of Antimicrobial Chemotherapy. 2021 May 25.*

41. Najafi F, Izadi N, Hashemi-Nazari SS, **Khosravi-Shadmani F**, Nikbakht R, Shakiba E. Serial interval and time-varying reproduction number estimation for COVID-19 in western Iran. *New microbes and new infections. 2020 Jul 1;36:100715.*

42. James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, Hamilton EB, Liu Z, McCracken D, Nixon MR, Sylte DO,...,**Khosravi Shadmani F**,..... Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. *Injury prevention. 2020 Jan 8.*

43. Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, Sharif M, Khatibian M, Fitzmaurice C, Nixon MR, Abbasi N, ..., **Khosravi Shadmani F**, The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*. 2019 Dec 1;4(12):934-47.
44. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, Ansari R, Roshandel G, Merat S, Fitzmaurice C, Force LM, ..., **Khosravi Shadmani F**, The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*. 2019 Dec 1;4(12):913-33.
45. Mansori K, Shiravand N, **Khosravi Shadmani F**, Moradi Y, Allahmoradi M, Ranjbaran M, Ahmadi S, Farahani A, Samii K, Valipour M. Association between depression with glycemic control and its complications in type 2 diabetes. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019 Mar 1;13(2):1555-60.
46. **Khosravi Shadmani F**, Mansori K, Khazaei S, Mansouri Hanis S, Khazaei S, Sani M, Ayubi E. Geographic distribution of breast cancer incidence in Iran. *Biomed Res Ther*. 2017.
47. **Khosravi Shadmani F**, Mansori K, Karami M, Zayeri F, Shadman RK, Hanis SM, Soori H. Avoidable burden of risk factors for serious road traffic crashes in Iran: a modeling study. *Journal of preventive medicine and public health*. 2017 Mar; 50(2):83
48. **Khosravi Shadmani F**, Ayubi E, Khazaei S, Sani M, Hanis SM, Khazaei S, Soheylizad M, Mansori K. Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study. *Epidemiology and health*. 2017;39.
49. **Khosravi Shadmani F**, Soori H, Karami M, Zayeri F. Priority setting of preventive intervention for road traffic injuries in Iran. *Iranian Journal of Epidemiology*. 2014 Jun 15;10(1):33-44.
50. **Khosravi Shadmani F**, Karami M. Joint effect of modifying selected risk factors on attributable burden of cardiovascular diseases. *International journal of preventive medicine*. 2013 Dec;4(12):1461.
51. **Khosravi Shadmani F**, Soori H, Mansori K, Karami M, Ayubi E, Khazaei S. Estimation of the population attributable fraction of road-related injuries due to speeding and passing in Iran. *Epidemiology and health*. 2016;38.

52. Karami M, Mobasheri F, **Khosravi Shadmani F (corresponding author)**. Potential Impact Fraction of modifying selected risk factors on burden of cardiovascular disease in Iran: comparative risk assessment. *Razi journal of medical sciences*. 2013 Jul 15;20(109):62-71.
53. Mansori K, Khazaei S, **Khosravi Shadmani F**, Hanis SM, Jenabi E, Soheylizad M, Sani M, Ayubi E. Global Inequalities in Cervical Cancer Incidence and Mortality. *Middle East Journal of Cancer*. 2018 Jun 25;9(3):235-42.
54. Chaichian S, Khateri S, Moradi Y, **Khosravi Shadmani F**, Mansori K, Khazaei Z, Moradpour F, Varse F. Trends in cervical cancer incidence in Iran from 2003 to 2009. *Middle East Journal of Cancer*. 2017 Dec 30;9(1):57-63.
55. Khazaei S, Mansori K, Soheylizad M, Gholamalilee B, **Khosravi Shadmani F** Khazaei Z, Ayubi E. Epidemiology of lung cancer in Iran: sex difference and geographical distribution. *Middle East Journal of Cancer*. 2017 Sep 16;8(4):223-8.
56. Mansori K, Ayubi E, **Khosravi Shadmani F**, Hanis SM, Khazaei S, Sani M, Moradi Y, Khazaei S, Mohammadbeigi A. Estimates of global HIV/AIDS mortality, prevalence and incidence rates, and their association with the Human Development Index. *Biomedical Research and Therapy*. 2017 Jun 27;4(06):1400-10.
57. Mansori K, Hanis SM, **Khosravi Shadmani F**. Postpartum modern contraceptive use in northern Ethiopia: prevalence and associated factors-methodological issues in this cross-sectional study. *Epidemiology and health*. 2017 May 10;39.
58. Khazaei S, Ayubi E, Mansori K, Gholamalilee B, Khazaei S, **Khosravi Shadmani F**, Soheylizad M, Sani M, Hanis SM. Geographic, sex and age distribution of esophageal cancer incidence in Iran: A population-based study. *Middle East Journal of Cancer*. 2017 Mar 8;8(2):103-8.
59. Ebadi Fardazar F, Mansori K, Solhi M, Hashemi SS, Ayubi E, **Khosravi Shadmani F**, Khazaei S. A cross-sectional study for determinations of prevention behaviors of domestic accidents in mothers with children less than 5-year. *International Journal of Pediatrics*. 2016;4(5):1679-85.
60. Rostami F, Nadi A, Abedi G, Moosazadeh M, Abedini E, **Khosravi Shadmani F**, Mansori K. Relationship between the patients' sense of security and the gap in the quality of services in hospitals of Sari city, Iran. *Cukurova Medical Journal*. 2018 Jan 1;43(4):958-66.

61. **Khosravi Shadmani F**, Khazaei S, Hanis SM, Mansori K. Comment on: "Comparison of new adiposity indices for the prediction of body fat in hospitalized patients". *Nutrition*. 2018 Jun 1;50:104.
62. **Khosravi Shadmani F**, Mansori K. Comment on: Cancer Pain With a Neuropathic Component: A Cross-sectional Study of Its Clinical Characteristics, Associated Psychological Distress, Treatments, and Predictors at Referral to a Cancer Pain Clinic. *Journal of pain and symptom management*. 2018 Apr 11.
63. **Khosravi Shadmani F**, Mansouri Hanis S, Mansori K. Early food allergy and respiratory allergy symptoms, and attention-deficit/hyperactivity disorder in Chinese children: a cross-sectional study: Methodological issues. *Pediatr Allergy Immunol*. 2018 Apr 2.
64. **Khosravi Shadmani F**, Khazaei S, Hanis SM, Mansori K. Comment on: Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study. *Clinical Nutrition*. 2018 Apr 1;37(2):758.
65. **Khosravi Shadmani F**, Khazaei S, Mansouri Hanis S, Mansori K. Comment on: Complement C3 and fatty liver disease in Rheumatoid arthritis patients: A cross-sectional study. *Eur J Clin Invest*. 2018.
66. Hanis SM, **Khosravi Shadmani F**, Mansori K. Letter to editor: The waist circumference-adjusted associations between hyperuricemia and other lifestyle-related diseases: methodological issues in cross-sectional study. *Diabetology & metabolic syndrome*. 2017 Dec;9(1):23.
67. **Khosravi Shadmani F**, Hanis SM, Mansori K. Association between bone scan index and activities of daily living in patients with advanced non-small cell lung cancer: methodological issues in cross-sectional study. *Supportive Care in Cancer*. 2017 Nov 1;25(11):3291-.
68. **Khosravi Shadmani F**, Hanis SM, Mansori K. The influence of resilience on mental health: The role of general well-being: Methodological issues to avoid prediction fallacy in a cross-sectional study. *International journal of nursing practice*. 2017;23(3).
69. Karami, M, **Khosravi Shadmani F**, and Najafi F. "Estimating the contribution of diabetes on the attributable burden of cardiovascular diseases in Kermanshah, West of Iran." *Iranian Journal of Epidemiology* 8, no. 3 (2012): 33-38.

70. **Khosravi Shadmani F**, Soori H, Karmi M, Zayeri F, Mehmandar MR. "Estimating of Population Attributable Fraction of Unauthorized Speeding and Overtaking on Rural Roads of Iran." *Iranian Journal of Epidemiology* 8, no. 4 (2013): 9-14.
71. Moradi Y, **Khosravi Shadmani F**, Mansori K, Hanis SM, Khateri R, Mirzaei H. Prevalence of underweight and wasting in Iranian children aged below 5 years: a systematic review and meta-analysis. *Korean journal of pediatrics*. 2018 Aug;61(8):231.
72. Paydar P, Asadikaram G, Nejad HZ, Moazed V, Poursayedi B, Nematollahi MH, ..., **Khosravi Shadmani F**. The Role of Acetylcholinesterase, Paraoxonase, and Oxidative Stress in Breast Tumors. 2018;11(11).
73. Mansori K, **Khosravi Shadmani F**, Mirzaei H, Vesal Azad R, Khateri S, Mansouri Hanis S, et al. Prevalence of stunting in Iranian children under five years of age: Systematic review and meta-analysis. 2018;32(1):598-604.
74. Najafi F, **Khosravi Shadmani F**, Ghalandari M, Darbandi M. Disability-adjusted life years and mortality rate attributed to unsafe sex and drug use for AIDS in the Middle East and North Africa countries. *Archives of Public Health*. 2020 Dec;78(1):1-2.
75. Borojeni HR, Najafi F, **Shadmani FK**, Darabi Z, Darbandi M, Farhadi K, Borojeni SS, Maleki S, Naderi M. Disability-Adjusted Life Years and Mortality Rate Attributed to Brain and Central Nervous System Cancer in the Middle East and North Africa Countries. *Neuroepidemiology*. 2021;55(6):447-59.
76. Jesmani Y, Bozorgomid A, **Shadmani FK**, Dehbani A, Sayad B. Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave. *Vacunas*. 2023 Feb 13.
77. Ahmadi F, Fallah Z, **Shadmani FK**, Allahmoradi M, Salahshoor P, Ahmadi S, Mansori K. Relationship between incidence and mortality of asthma with PM2. 5, ozone, and household air pollution from 1990 to 2106 in the world: An ecological study. *The Egyptian Journal of Chest Diseases and Tuberculosis*. 2022 Oct 1;71(4):457.

Conference Presentations

A) Oral

- 1- Estimating the population attributable fraction of road related injuries due to speeding and passing in Iran, the 7th Iranian Epidemiology congress, 2013*
- 2- Priority Setting of Preventive Intervention for Road Traffic Injuries in Iran, the 15 International Conference on Traffic and Transportation Engineering, 2015*
- 3- National and subnational levels achievement to Sustainable Development Goals (SDGs) for non- communicable diseases in Iran: modelling study with scenario-based projection, 9th Iranian Congress of epidemiology, 2019*
- 4. Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study, 2023*
- 5. Investigating avoidable breast cancer deaths due to obesity at national and subnational levels, 2023*

B) Poster

- 1- Potential Impact Fraction of modifying selected risk factors on burden of cardiovascular disease in Iran: comparative risk assessment, the 7th Iranian Epidemiology congress, 2013*
- 2- The effect of multiple chronic condition on the quality of life in Iran elderly people, the 8th Iranian Epidemiology congress and 1st international congress of clinical Epidemiology, 2016*
- 3- Does Iran achieve the Sustainable Development Goals for Non Communicable Diseases? GBD 20th Anniversary Symposium Poster Session; 2017 September 26; Washington, USA.*

Teachings

Epidemiology's methods for MSc epidemiology,

Epidemiology for BSc Nutrition,

Epidemiology for BSc Public Health,

Research methodology for BSc Medical Records,

Research methodology for BSc Health Technology

Programming in Satat for faculty Members and Ph.D students

Burden of diseases for faculty Members

Epidemiology's methods for MSc epidemiology

Epidemiology for BSc Nursing

Social Epidemiology for Ph.D of Epidemiology

Data science for Ph.D of Epidemiology

Case_ Control course for Ph.D of Epidemiology

Projects

A) Finished projects

- 1. Estimating the potential impact fraction of the preventive interventions for road traffic injuries in Iran, as project manager*
- 2. Assessing the association of Acute Coronary Syndrome and social economic status in Kermanshah, as project manager*
- 3. Excess mortality of Heart and respiratory diseases due to dust in Kermanshah province, as project manager*
- 4. Estimating incidence rate of Acute Coronary Syndrome in Kermanshah, as project manager*
- 5. Sex differences in Acute Coronary Syndrome in Kermanshah, as project manager*
- 6. Acute Coronary Syndrome in diabetic patients in Kermanshah, as project manager*
- 7. Epidemiologic pattern and years of life lost due to intentional and unintentional injuries in Kurdistan province in 2012, as project manager*
- 8. Burden of burn in Kermanshah province in 2012, as project manager*
- 9. Estimation of deaths of road traffic injuries in Kermanshah province in 2012: capture recapture method, as project manager*
- 10. The Relationship between Occupational Stress & Related Injuries among Physician's Assistants: A Case-Control Study, as project manager*
- 11. Epidemiologic pattern in empyema patient in Mashih Daneshvari hospital in 1998-2012, as project assistant*
- 12. Epidemiologic pattern and years of life lost due to premature death and its trend in Kermanshah province in 2006-2012, as project manager*

13. *Epidemiologic pattern and geographical distribution of road traffic injuries in pedestrian with the use of Gographical Information System (GIS), as project manager*
14. *Comparing practical treatment with international guidelines in Acute Coronary Syndrome in Kermanshah, as project manager*
15. *The effectiveness of HBV vaccination in Imam Reza hospital staff in Kermanshah, as project assistant*
16. *The effectiveness and the health of Peginterferon with Ribavirin in HCV hemophilia and talasemia patients , as project assistant*
17. *Knowledge and attitude for safety belt in parents, as project assistant*
18. *Pattern of internet use in high school students in Tehran , as project assistant*
19. *Prevalence of coronary problems in HIV patients in kermanshah city, 2012, as project assistant*
20. *Incidence rate, risk factors and outcome of Acute Coronary Syndrome in Kermanshah(2011-2012), as project manager*
21. *Incidence rate and survival of cancers in kermanshah province: a cohort study , as project assistant*
22. *The use of pilot phase of 2010 public census in implementation of determining mortality of maternal deaths with RAMOS, as project assistant*
23. *National and subnational levels achievement to Sustainable Development Goals(SDGs) for non-communicable diseases in Iran: modeling study with scenario-based projection, as project manager*
24. *Association between some organochlorine pestiside used in agriculture with epigenetic alterations in breast cancer patients in kerman province during 2016-2017 , as project assistant*
25. *Estimating the trend of burden of HIV's risk factors in MENA region: from 1990 t0 2017, as project assistant*
26. *The distribution and effects of the environmental carcinogens in Iran's population, as project assistant*
27. *Investigating the relationship between influenza vaccine and complications of covid-19 vaccine: a retrospective cohort study*
28. *Estimating the burden attributed to high body mass index in osteoarthritis in Iran*
29. *Geospatial evaluation of COVID-19 mortality: Influence of socio-economic status and underlying health conditions in Kermanshah*

30. *Estimation of economic burden of COVID-19 mortality in social classes - a case study of Kermanshah metropolis*
31. *Evaluation of the effectiveness of vaccines used on the incidence and mortality rates of Covid-19 Hamedan provinc in 2021-2022*
32. *The effect of smoking and diabetes on women breast cancer in North Africa and the Middle East from 1990 to 201*
33. *The national and subnational burden and mortality of cancers in Iran*
34. *Evaluation of retinal vascular changes in patients that improved COVID 19 using OCT-A data analysis*
35. *Risk factors and causes associated with mortality in COVID-19 patients admitted to Farabi Hospital in Kermanshah*
36. *Survey prevalence of corona virus infection and it's related factors in Ravansar cohort population in 2020-2021*
37. *Predicting the Incidence of coronavirus and its related factors: a Markov switching model*
38. *Epidemiology of coronavirus disease 2019 (COVID-19) in children 1 to 59 months, Kermanshah province since the beginning the epidemic*
39. *Trend and projection of mortality causes from non-communicable diseases in Iran*
40. *Reassessment of participants of population-based cohort of non-communicable disease in Ravansar*
41. *Outcomes of pregnancy and neonatal in pregnant women with Covid-19*
42. *Association of Oral Hygiene with Chronic Systemic Diseases*
43. *Trend and projection of number of death and mortality rate due to cardiovascular diseases in Iran: 2001-2030*
44. *Projection of trend of non communicable diseases risk factors in Iran*
45. *Evaluation of the effectiveness of Covid 19 vaccines on the indicators of Covid 19 disease*
46. *Monitoring and active surveillance of adverse events following the booster dose of AstraZeneca vaccine in people vaccinated with Sinopharm vaccines: A Cohort Study*
47. *Analysis of the status of salt consumption and its related factors in the general population of Kermanshah: providing suggestions and solutions*

48. *Measuring the serum concentration of BMP10 and the inflammatory marker NT-proBNP and the gene expression of GATA6 in cardiovascular patients and investigating the relationship of these factors with patients with chronic rheumatoid arthritis*
49. *Comparison of anthropometric indices for predicting the risk of metabolic Diseases: a population-based study*
50. *Evaluation of serum ferritin level and its relationship with disease severity and 6-minute walk test in patients with heart failure admitted to Imam Ali Hospital, Kermanshah*
51. *Investigation of left ventricular function status and functional valvular insufficiency in STEMI and NSTEMI patients from January 2018 to december 2021 in Imam Ali Hospital, Kermanshah*
52. *Second phase of diagnosable congenital anomalies registry at birth in Kermanshah*
53. *Estimating the attributable fraction of preventive interventions for non-communicable diseases in Iran using attributable deaths*
54. *Evaluation of the burden, mortality and incidence of pancreatic cancer and 2030 projection in Iran in 1990-2019*
55. *Epidemiological characteristics and outcomes of COVID-19 hospitalized patients in Iran :a retrospective multicenter study*
56. *Investigating the incidence of cardiovascular diseases, type 2 diabetes and hypertension and their determinants: five and ten year prediction of future trends*
57. *The national and subnational burden and mortality of cancers in Iran*
58. *Estimating the burden attributed to high body mass index in osteoarthritis in Iran*

B) Ongoing projects

1. *Investigating the pattern of nutritional changes and the factors affecting it in the population covered by Persian cohort*
2. *Optimization for Locating Emergency station in Kermanshah province*
3. *Third phase of diagnosable congenital anomalies registry at birth in Kermanshah in 2025*

4. *Assessment and analysis of the Health Status of Workers in Ehya Sepahan Iron Ore Mine*
5. *Investigation of Quality of Life Among People with Disabilities and Its Influencing Factors in Iran: A Cross-Sectional Study*
6. *The trend of fatal traffic accidents and their location in Kermanshah province from 2012 to 2024*
7. *The attributable fraction of papillomavirus in the incidence and prevalence of cervical cancer in Iran*
8. *The attributable fraction of obesity in mortality from non-communicable diseases in Iran*
9. *Examination of risk factors associated with birth defects among newborns in Kermanshah: A case-control study*
10. *Investigating the effect of different types of covid-19 vaccination on reducing the risk of mortality in Kermanshah province in 1400*

TAUGHT WORKSHOPS

- | | |
|------|--|
| 2013 | <i>Sample size and power analysis</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2013 | <i>Research methodology</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2013 | <i>Design of clinical trials</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2013 | <i>Bias in clinical research</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2013 | <i>The analysis of questionnaire</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2018 | <i>programming in stata</i>
<i>Kerman University of Medical Sciences, Kerman, Iran</i> |
| 2018 | <i>Burden of diseases workshop for faculty Members, 30 hours</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2020 | <i>Power BI workshop</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |
| 2022 | <i>web of sciences and scopus workshop</i>
<i>Kermanshah University of Medical Sciences, Kermanshah, Iran</i> |

- 2022 *Evidence Based Medicine (EBM) Workshop for faculty Members*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2022 *Advanced Stata workshop*
Iranian Epidemiological Association, Tehran, Iran
- 2022 *Advanced visualization in R and STATA*
Iranian Epidemiological Association, Tehran, Iran
- 2023 *Scientific writing*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2023 *Proposal and report writhing workshop*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2023 *Critical appraisal of clinical trial studies*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2024 *web of sciences and scopus workshop*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2024 *Registries*
Kermanshah University of Medical Sciences, Kermanshah, Iran
- 2025 *Advanced visualization in R and STATA*
Zanjan University of Medical Sciences, Zanjan, Iran
- 2025 *Systematic review and misanalysis*
Zanjan University of Medical Sciences, Zanjan, Iran
- 2025 *Evidence Based Medicine (EBM)*
Zanjan University of Medical Sciences, Zanjan, Iran
- 2025 *STATA workshop*
Zanjan University of Medical Sciences, Zanjan, Iran

ATTENDED WORKSHOPS

- *Systematic Review and Meta-Analysis*
- *Workshop on advanced analyzing mortality level and cause of death data*
- *Burden and risk factor for noncommunicable disease*
- *Decision Tree Modeling*
- *Estimation of Missing Data*
- *Tree Age Modeling*
- *Time Series Analysis*
- *Numerical Methods in Modeling Problems*

- *High Dimensional Data Analysis*
- *Markov Modeling*
- *Data Mining in Medical Sciences*
- *Machine learning techniques and tools*
- *Recurrent Analysis and Cure Models*
- *Size Estimation of Hidden Groups*
- *RCT-GCP*
- *Scientific writhing a paper*
- *Dynamic models*
- *GIS workshop*
- *Survival in Cancers*
- *Stata programming*
- *R programing*
- *Sampling*
- *Burden of Disease*
- *Bias and confounding in longitudinal studies*
- *Lessons from longitudinal studies*
- *Programming in Matlab*
- *Qualitative studies*
- *Case control, case cohort and nested cohort studies analysis*

SOFTWARE SKILLS

STATA (Advanced)

R (Medium)

SPSS (Advanced)

Microsoft Office (Advanced)

ArcGIS (Intermediate)

Research line

Non communicable diseases

Modeling

Policy Making

Prediction and Projection

Data Visualization

Data science

Interests

Comparative risk assessment, Burden of Diseases, Policy Making